
Jun 12, 2026
Danaher Closes Masimo Deal Shifting Monitoring Story Inside Diagnostics Platform
Danaher has finalized its acquisition of Masimo, integrating the company into its Diagnostics segment, which marks a significant shift in the patient monitoring landscape.This $9.5 billion cash deal ends Masimo's tenure as an independent public entity and introduces a new governance structure under Danaher. As a result, Masimo's shares have been delisted from Nasdaq, transitioning from a standalone equity story to one embedded within Danaher's broader diagnostics platform. This integration could









